Review



human il 6r gp130 neutralizing antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    R&D Systems human il 6r gp130 neutralizing antibody
    Cisplatin resistance in HNSCC cell lines was independent of <t>IL-6/gp130/STAT3</t> signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).
    Human Il 6r Gp130 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+6r+gp130+neutralizing+antibody/Human+gp130+Antibody/pmc04869939-54-12-18
    Average 90 stars, based on 9 article reviews
    human il 6r gp130 neutralizing antibody - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma"

    Article Title: Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma

    Journal: Oncology Reports

    doi: 10.3892/or.2016.4765

    Cisplatin resistance in HNSCC cell lines was independent of IL-6/gp130/STAT3 signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).
    Figure Legend Snippet: Cisplatin resistance in HNSCC cell lines was independent of IL-6/gp130/STAT3 signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).

    Techniques Used: Recombinant, Control, Inhibition, Expressing

    Related Articles

    Cell Culture:

    Article Title: Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
    Article Snippet: .. Cells were also cultured in the presence of human recombinant IL-6 or human IL-6R/gp130 neutralizing antibody (all from R&D Systems, Minneapolis, MN, USA) for 24 h, followed by 5 μ M cisplatin treatment to examine changes in drug resistance. .. Cells were further grown for 72 h, before incubated in 50 μ l XTT labeling mixture (Roche Molecular Biochemicals, Mannheim, Germany) for 4 h, and then scanned at 450 nm.

    Recombinant:

    Article Title: Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
    Article Snippet: .. Cells were also cultured in the presence of human recombinant IL-6 or human IL-6R/gp130 neutralizing antibody (all from R&D Systems, Minneapolis, MN, USA) for 24 h, followed by 5 μ M cisplatin treatment to examine changes in drug resistance. .. Cells were further grown for 72 h, before incubated in 50 μ l XTT labeling mixture (Roche Molecular Biochemicals, Mannheim, Germany) for 4 h, and then scanned at 450 nm.



    Similar Products

    human il 6r gp130 neutralizing antibody  (R&D Systems)
    90
    R&D Systems human il 6r gp130 neutralizing antibody
    Cisplatin resistance in HNSCC cell lines was independent of <t>IL-6/gp130/STAT3</t> signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).
    Human Il 6r Gp130 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+6r+gp130+neutralizing+antibody/Human+gp130+Antibody/pmc04869939-54-12-18
    Average 90 stars, based on 1 article reviews
    human il 6r gp130 neutralizing antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Cisplatin resistance in HNSCC cell lines was independent of IL-6/gp130/STAT3 signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).

    Journal: Oncology Reports

    Article Title: Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma

    doi: 10.3892/or.2016.4765

    Figure Lengend Snippet: Cisplatin resistance in HNSCC cell lines was independent of IL-6/gp130/STAT3 signaling pathway. (A and B) Neither exogenous IL-6 nor IL-6 pathway inhibitors affected cisplatin resistance in HNSCC cell lines. Cells were grown in the presence (+) or absence (−) of human IL-6 receptor neutralizing antibody (40 µ g/ml; A), human gp130 neutralizing antibody (60 µ g/ml; A) or human recombinant IL-6 (100 ng/ml; B), for 24 h and then treated with (+) or without (−) 5 µ M cisplatin. Cells without any treatment were set as control. NS, not significant (p>0.05; n=5, paired Student's t-test). (C and D) Effect of cisplatin (C and D), exogenous IL-6 (D), anti-IL-6 antibody (C and D) and anti-gp130 antibody (C) on the acquired cisplatin resistant C12cis (C) cell line and sensitive C12 cell line (D). Whereas IL-6 induced p-STAT3 Tyr705 in C12 cell line through IL-6R, unstimulated C12cis cells had p-STAT3 Tyr705 that was unchanged after IL-6 receptor inhibition. (E) IL-6/STAT3 pathway was reduced in the acquired cisplatin-resistant cell lines. (F and G) Acquired cisplatin-resistant cell lines had decreased IL-6R mRNA and protein levels. The mRNA expression levels were normalized to housekeeping gene TBP ( * p<0.05, ** p<0.01 and *** p<0.001; n=4, paired Student's t-test).

    Article Snippet: Cells were also cultured in the presence of human recombinant IL-6 or human IL-6R/gp130 neutralizing antibody (all from R&D Systems, Minneapolis, MN, USA) for 24 h, followed by 5 μ M cisplatin treatment to examine changes in drug resistance.

    Techniques: Recombinant, Control, Inhibition, Expressing